China Meheco Company Overview
- Year Founded
-
1983
- Status
-
Public
- Employees
-
7,949
- Stock Symbol
-
600056
- Investments
-
6
- Share Price
-
$1.31
- (As of Thursday Closing)
China Meheco Company General Information
Description
China Meheco Group Co Ltd is engaged in the distribution and trading of botanical medicines, medical instruments, and pharmaceuticals. It offers botanic medicines and herbal products, as well as exports of natural medicines, including herbs, spices, plant extracts, bee products, and Chinese traditional medicines. The company's business scope covers the whole industry chain, from research and development, cultivation and processing, manufacturing, distribution, and logistics to international trading, academic promotion, and technical service. The corporation provides trading services for customers in the pharmaceutical and chemical field, covering APIs, preparations, biologicals, blood products, and others.
Contact Information
Website
www.meheco.comCorporate Office
- Floors 21-24,Block B, UniversaTimes Center, Number 1 zone, Courtyard1
- Xiying Street, Fengtai District
- Beijing, Beijing 100073
- China
Corporate Office
- Floors 21-24,Block B, UniversaTimes Center, Number 1 zone, Courtyard1
- Xiying Street, Fengtai District
- Beijing, Beijing 100073
- China
China Meheco Company Stock Performance
As of 12-Nov-2026, China Meheco Company’s stock price is $1.31. Its current market cap is $1.96B with 1.5B shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.31 | $1.31 | $1.22 - $1.70 | $1.96B | 1.5B | 10.9M | $0.03 |
China Meheco Company Financials Summary
As of 30-Sep-2026, China Meheco Company has a trailing 12-month revenue of $5B.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 2,869,086 | 3,107,187 | 3,060,569 | 3,041,597 |
| Revenue | 4,998,993 | 4,917,264 | 4,911,659 | 5,487,645 |
| EBITDA | 139,104 | 230,888 | 228,266 | 315,129 |
| Net Income | 44,914 | 65,806 | 81,191 | 148,135 |
| Total Assets | 5,774,204 | 5,269,766 | 4,975,483 | 5,277,475 |
| Total Debt | 977,854 | 751,719 | 883,145 | 792,882 |
China Meheco Company Patents
China Meheco Company Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2021134407-A1 | Method for extracting crude product of glycyrrhizic acid and glycyrrhizic flavone from licorice and purifying to obtain glycyrrhizinate | Inactive | 31-Dec-2019 | ||
| WO-2021134408-A1 | Preparation, impurity removal and purification methods for glycyrrhizic acid monovalent salt | Inactive | 31-Dec-2019 |
China Meheco Company Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
China Meheco Company Investments & Acquisitions (6)
China Meheco Company’s most recent deal was a Merger/Acquisition with HQ Pharma for . The deal was made on 30-Dec-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| HQ Pharma | 30-Dec-2025 | Merger/Acquisition | Drug Delivery | ||
| Jinsui Technology | 12-May-2025 | Merger/Acquisition | Other Healthcare Services | ||
| Innostar | 27-Jan-2015 | Secondary Transaction - Private | Other Pharmaceuticals and Biotechnology | ||
| Shanghai Hutchison Whampoa | 16-Apr-2014 | Secondary Transaction - Private | Distributors/Wholesale | ||
| Beijing Xinxing Huakang | 27-Mar-2012 | Merger/Acquisition | Distributors (Healthcare) |
China Meheco Company ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
37.73 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,585
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Pharmaceuticals
Subindustry
of 354
Rank
Percentile
China Meheco Company Exits (3)
China Meheco Company’s most recent exit was on 27-Jan-2015 from Innostar. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Innostar | 27-Jan-2015 | Completed |
|
||
| Shanghai Hutchison Whampoa | 16-Apr-2014 | Completed |
|
||
| Wuhan Grand Pharmaceutical | 24-Oct-2002 | Secondary Transaction - Private | Completed |
|
China Meheco Company Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Jinsui Technology | Beijing, China | 1993 |
China Meheco Company FAQs
-
When was China Meheco Company founded?
China Meheco Company was founded in 1983.
-
Where is China Meheco Company headquartered?
China Meheco Company is headquartered in Beijing, China.
-
What is the size of China Meheco Company?
China Meheco Company has 7,949 total employees.
-
What industry is China Meheco Company in?
China Meheco Company’s primary industry is Pharmaceuticals.
-
Is China Meheco Company a private or public company?
China Meheco Company is a Public company.
-
What is China Meheco Company’s stock symbol?
The ticker symbol for China Meheco Company is 600056.
-
What is the current stock price of China Meheco Company?
As of 12-Nov-2026 the stock price of China Meheco Company is $1.31.
-
What is the current market cap of China Meheco Company?
The current market capitalization of China Meheco Company is $1.96B.
-
What is China Meheco Company’s current revenue?
The trailing twelve month revenue for China Meheco Company is $5B.
-
What is China Meheco Company’s annual earnings per share (EPS)?
China Meheco Company’s EPS for 12 months was $0.03.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
